autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB
3 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for glioblastoma | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for gliosarcoma | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for oligodendroglioma | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |